146 related articles for article (PubMed ID: 25829525)
1. Processes of discontinuing chemotherapy for metastatic non-small-cell lung cancer at the end of life.
Pirl WF; Greer JA; Irwin K; Lennes IT; Jackson VA; Park ER; Fujisawa D; Wright AA; Temel JS
J Oncol Pract; 2015 May; 11(3):e405-12. PubMed ID: 25829525
[TBL] [Abstract][Full Text] [Related]
2. Psychological factors at early stage of treatment as predictors of receiving chemotherapy at the end of life.
Fujisawa D; Temel JS; Traeger L; Greer JA; Lennes IT; Mimura M; Pirl WF
Psychooncology; 2015 Dec; 24(12):1731-7. PubMed ID: 25959002
[TBL] [Abstract][Full Text] [Related]
3. Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer.
Greer JA; Pirl WF; Jackson VA; Muzikansky A; Lennes IT; Heist RS; Gallagher ER; Temel JS
J Clin Oncol; 2012 Feb; 30(4):394-400. PubMed ID: 22203758
[TBL] [Abstract][Full Text] [Related]
4. Metastatic non-small cell lung cancer: a benchmark for quality end-of-life cancer care?
Philip J; Hudson P; Bostanci A; Street A; Horey DE; Aranda S; Zordan R; Rumbold BD; Moore G; Sundararajan V
Med J Aust; 2015 Feb; 202(3):139-43. PubMed ID: 25669476
[TBL] [Abstract][Full Text] [Related]
5. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
6. Timing of palliative care needs reporting and aggressiveness of care near the end of life in metastatic lung cancer: A national registry-based study.
Goldwasser F; Vinant P; Aubry R; Rochigneux P; Beaussant Y; Huillard O; Morin L
Cancer; 2018 Jul; 124(14):3044-3051. PubMed ID: 29742292
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer.
Murillo JR; Koeller J
Oncologist; 2006; 11(10):1095-9. PubMed ID: 17110629
[TBL] [Abstract][Full Text] [Related]
8. [Limitations of palliative chemotherapy, application to lung cancer: the point of view of hospital pharmacists].
Demange C; Thiébaux I
Bull Cancer; 2003 Mar; 90(3):284-8. PubMed ID: 12801830
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
Koch A; Fohlin H; Sörenson S
J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
[TBL] [Abstract][Full Text] [Related]
10. Combined regional and systemic chemotherapy for advanced and inoperable non-small cell lung cancer.
Müller H
Eur J Surg Oncol; 2002 Mar; 28(2):165-71. PubMed ID: 11884052
[TBL] [Abstract][Full Text] [Related]
11. Family Perspectives on Aggressive Cancer Care Near the End of Life.
Wright AA; Keating NL; Ayanian JZ; Chrischilles EA; Kahn KL; Ritchie CS; Weeks JC; Earle CC; Landrum MB
JAMA; 2016 Jan; 315(3):284-92. PubMed ID: 26784776
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
[TBL] [Abstract][Full Text] [Related]
13. Aggressiveness of cancer-care near the end-of-life in Korea.
Keam B; Oh DY; Lee SH; Kim DW; Kim MR; Im SA; Kim TY; Bang YJ; Heo DS
Jpn J Clin Oncol; 2008 May; 38(5):381-6. PubMed ID: 18411260
[TBL] [Abstract][Full Text] [Related]
14. Impact of Palliative Chemotherapy and Travel Distance on Hospice Referral in Patients With Stage IV Pancreatic Cancer: A Retrospective Analysis Within a Veterans Administration Medical Center.
Duff JM; Thomas RM
Am J Hosp Palliat Care; 2018 Jun; 35(6):875-881. PubMed ID: 29216749
[TBL] [Abstract][Full Text] [Related]
15. Aggressiveness of care in a prospective cohort of patients with advanced NSCLC.
Temel JS; McCannon J; Greer JA; Jackson VA; Ostler P; Pirl WF; Lynch TJ; Billings JA
Cancer; 2008 Aug; 113(4):826-33. PubMed ID: 18618579
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy and palliative care near end-of life: examining the appropriateness at a cancer institute for colorectal cancer patients.
Massa I; Nanni O; Foca F; Maltoni M; Derni S; Gentili N; Frassineti GL; Casadei Gardini A; Valgiusti M; Amadori D; Prati E; Altini M; Gallegati D; Sansoni E
BMC Palliat Care; 2018 Jun; 17(1):86. PubMed ID: 29914452
[TBL] [Abstract][Full Text] [Related]
17. Referral patterns in advanced non-small cell lung cancer: impact on delivery of treatment and survival in a contemporary population based cohort.
Noonan K; Tong KM; Laskin J; Melosky B; Sun S; Murray N; Ho C
Lung Cancer; 2014 Dec; 86(3):344-9. PubMed ID: 25439436
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Hospice Consultation on Aggressive Treatment of Lung Cancer.
Yoo SH; Keam B; Kim M; Kim TM; Kim DW; Heo DS
Cancer Res Treat; 2018 Jul; 50(3):720-728. PubMed ID: 28707460
[TBL] [Abstract][Full Text] [Related]
19. [Chemotherapy at the end of life for patients with lung cancer. A practice analysis].
Sesé L; Didier M; Rousseau-Bussac G; Crequit P; Masanes MJ; Chouaid C
Rev Mal Respir; 2015 Mar; 32(3):256-61. PubMed ID: 25847203
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
Feigenberg SJ; Hanlon AL; Langer C; Goldberg M; Nicolaou N; Millenson M; Coia LR; Lanciano R; Movsas B
J Thorac Oncol; 2007 Apr; 2(4):287-92. PubMed ID: 17409799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
